|
Hypoparathyroidism
|
0.010 |
Biomarker
|
disease |
BEFREE |
PARAT, a new European Society of Endocrinology program, aims to identify unmet scientific and educational needs of parathyroid disorders, such as primary hyperparathyroidism (PHPT), including parathyroid cancer (PC), and hypoparathyroidism (HypoPT).
|
31176307 |
2019 |
|
Parathyroid Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Management of parathyroid disorders is challenging, and PARAT has highlighted the need for international transdisciplinary scientific and educational studies in advancing in this field.
|
31176307 |
2019 |
|
Malignant tumor of parathyroid gland
|
0.010 |
Biomarker
|
disease |
BEFREE |
PARAT, a new European Society of Endocrinology program, aims to identify unmet scientific and educational needs of parathyroid disorders, such as primary hyperparathyroidism (PHPT), including parathyroid cancer (PC), and hypoparathyroidism (HypoPT).
|
31176307 |
2019 |
|
Hyperparathyroidism, Primary
|
0.010 |
Biomarker
|
disease |
BEFREE |
PARAT, a new European Society of Endocrinology program, aims to identify unmet scientific and educational needs of parathyroid disorders, such as primary hyperparathyroidism (PHPT), including parathyroid cancer (PC), and hypoparathyroidism (HypoPT).
|
31176307 |
2019 |
|
Parathyroid Gland Adenocarcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
PARAT, a new European Society of Endocrinology program, aims to identify unmet scientific and educational needs of parathyroid disorders, such as primary hyperparathyroidism (PHPT), including parathyroid cancer (PC), and hypoparathyroidism (HypoPT).
|
31176307 |
2019 |
|
Adenocarcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
The present study aimed to investigate the expression patterns of prothymosin-α (PTMA) and parathymosin (PTMS) in patients with squamous cell carcinoma (SCC), adenosquamous cell carcinoma (ASC) and adenocarcinoma (AC) of the gallbladder, and to assess their association with the clinicopathological characteristics and prognosis of the patients.
|
29541218 |
2018 |
|
Squamous cell carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The present study aimed to investigate the expression patterns of prothymosin-α (PTMA) and parathymosin (PTMS) in patients with squamous cell carcinoma (SCC), adenosquamous cell carcinoma (ASC) and adenocarcinoma (AC) of the gallbladder, and to assess their association with the clinicopathological characteristics and prognosis of the patients.
|
29541218 |
2018 |
|
Adenosquamous carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Prothymosin-α and parathymosin expression predicts poor prognosis in squamous and adenosquamous carcinomas of the gallbladder.
|
29541218 |
2018 |
|
Diffuse Large B-Cell Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In ER DLBCLs, CNVs were related to transcription regulation, cell cycle and apoptosis, with duplications of histone H1T (31%), deletions of DIABLO (26%), PTMS (21%) and CK2B (15%).
|
27276707 |
2016 |
|
Carcinoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Prothymosin alpha and parathymosin mRNA levels were found significantly elevated in well-differentiated carcinomas in relation to adenomas (p<0.05) and goitres (p<0.05), an event possibly linked to the proliferation activity of thyroid follicular cells.
|
17203893 |
2007 |
|
Malignant neoplasm of thyroid
|
0.010 |
Biomarker
|
disease |
BEFREE |
Further studies are required to establish prothymosin alpha and parathymosin as diagnostic proliferation markers in thyroid cancer, especially in cases of undetermined cellular morphology of follicular origin which reflect the most common cytohistopathological discrepancies.
|
17203893 |
2007 |
|
Goiter
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Prothymosin alpha and parathymosin mRNA levels were found significantly elevated in well-differentiated carcinomas in relation to adenomas (p<0.05) and goitres (p<0.05), an event possibly linked to the proliferation activity of thyroid follicular cells.
|
17203893 |
2007 |
|
Nodular Goiter
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
A semi-quantitative RT-PCR assay was developed to determine prothymosin alpha and parathymosin mRNA expression patterns in thyroid follicular cells obtained from the fine-needle aspiration biopsy specimens of patients diagnosed with simple nodular goitre, follicular adenoma, papillary and follicular well-differentiated carcinomas.
|
17203893 |
2007 |
|
Thyroid Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
Further studies are required to establish prothymosin alpha and parathymosin as diagnostic proliferation markers in thyroid cancer, especially in cases of undetermined cellular morphology of follicular origin which reflect the most common cytohistopathological discrepancies.
|
17203893 |
2007 |
|
Thyroid carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Further studies are required to establish prothymosin alpha and parathymosin as diagnostic proliferation markers in thyroid cancer, especially in cases of undetermined cellular morphology of follicular origin which reflect the most common cytohistopathological discrepancies.
|
17203893 |
2007 |